Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/48717
Title: Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats
Authors: RodriguezPerez, JC 
Losada, Antonio
Anabitarte, Aranzazu
Cabrera, Juan 
Llobet, Javier
Palop, Leocadia
Plaza, Celia
Keywords: Remnant Kidney Model
Glomerular Injury
Segmental Glomerulosclerosis
Cell-Proliferation
Hypertension, et al
Issue Date: 1997
Publisher: 0022-3565
Journal: Journal of Pharmacology and Experimental Therapeutics 
Abstract: Antihypertensive drugs have differing effects on renal hemodynamics and morphology. We analyzed whether the use of a new beta adrenoceptor antagonist and vasodilator, carvedilol (CVD), slows the progression of nephrosclerosis and whether the renoprotective effect as well as reduction in cardiac hypertrophy is dependent on the degree of blood pressure reduction. Fifty-four adult male Sprague-Dawley rats were distributed among five groups: group I served as untreated controls with 5/6 nephrectomy (Nx); group II, sham (no renal ablation or drug treatment); group III, CVD 5 (5/6 Nx and treatment with oral CVD at 5 mg/kg/day); group IV, CVD 10 (5/6 Nx and treatment with oral CVD at 10 mg/kg/day); and group V, CVD 20 (5/6 Nx and treatment with oral CVD at 20 mg/kg/day). Tail-cuff blood pressure and 24-hr urine samples were obtained before and at 3, 5 and II weeks of treatment with CVD. At the end of the study period, blood was taken to measure serum creatinine, plasma renin activity and CVD levels, as well as the remnant kidney and heart for morphological studies. There was a significant reduction in 24-hr U-ProtV in all the CVD-treated groups, and it was increasingly evident with the highest dose used. However, only rats receiving doses of 10 and 20 mg/kg/day of CVD exhibited significant decreases in blood pressure. Elevated serum creatinine levels seen in untreated controls were significantly decreased by CVD in treated rats (P < .01), indicating that. glomerular filtration rate was improved by this drug. This was associated with a significant increase in U-NaV. Concomitant and significant (P < .01) decreases in plasma renin activity were observed in sham and CVD-treated rats. CVD-treated animals had considerably reduced renal damage (P < .01) and cardiac hypertrophy (P < .01) compared with untreated controls. These data indicate that CVD is effective in delaying progression of renal damage and provides beneficial effects in the remnant kidney and cardiac hypertrophy, even at nonhypotensive doses.
URI: http://hdl.handle.net/10553/48717
ISSN: 0022-3565
Source: Journal Of Pharmacology And Experimental Therapeutics[ISSN 0022-3565],v. 283 (1), p. 336-344
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

22
checked on Sep 12, 2021

WEB OF SCIENCETM
Citations

22
checked on Sep 12, 2021

Page view(s)

28
checked on Sep 11, 2021

Google ScholarTM

Check


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.